Aceglumate

Aceglumate

SCHEMBL910300

CC(=O)NC(CCC(=O)O)C(=O)O.NC(=O)N1CCCCC1

nearest known ligand 0.46

Full drug profile on Sugi Atlas →

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
FOLH1 Q04609 7/20 0.46
NAALAD2 Q9Y3Q0 2/20 0.46
RIMKLA Q8IXN7 1/20 0.46
ITGB3 P05106 3/20 0.43
ITGA2B P08514 3/20 0.43
GNPAT O15228 1/20 0.43
POLB P06746 1/20 0.39
KDM4E B2RXH2 1/20 0.39
MAPT P10636 1/20 0.39
THRB P10828 1/20 0.39
ALOX15 P16050 1/20 0.39
NFKB1 P19838 1/20 0.39
PTGS2 P35354 1/20 0.39
THPO P40225 1/20 0.39
RECQL P46063 1/20 0.39
BLM P54132 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Acetylglutamic Acid SCHEMBL910770 1.00 FOLH1 (0.46) FOLH1NAALAD2RIMKLAITGB3ITGA2B
Acetylglutamic Acid SCHEMBL910067 1.00 FOLH1 (0.46) FOLH1NAALAD2RIMKLAITGB3ITGA2B
Aceglumate SCHEMBL910345 0.99 FOLH1 (0.47) FOLH1NAALAD2RIMKLAITGB3ITGA2B
Acetylglutamic Acid SCHEMBL910789 0.99 FOLH1 (0.47) FOLH1NAALAD2RIMKLAITGB3ITGA2B
Acetylglutamic Acid SCHEMBL910760 0.99 FOLH1 (0.47) FOLH1NAALAD2RIMKLAITGB3ITGA2B
Acetylglutamic Acid SCHEMBL716411 0.80 FOLH1 (0.69) FOLH1NAALAD2RIMKLAGNPATKDM4E
Aceglumate SCHEMBL198970 0.80 FOLH1 (0.69) FOLH1NAALAD2RIMKLAGNPATKDM4E
Acetylglutamic Acid SCHEMBL82128 0.80 FOLH1 (0.69) FOLH1NAALAD2RIMKLAGNPATKDM4E
Acetylglutamic Acid SCHEMBL2512801 0.80 FOLH1 (0.69) FOLH1NAALAD2RIMKLAGNPATKDM4E
SCHEMBL1604394 0.79 FOLH1 (0.55) FOLH1NAALAD2RIMKLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110004019-A1 Parakeratosis Inhibitor, Pore-Shrinking Agent, Or Rough Skin Inhibiting/Ameliorating Agent, And External Composition For Skin Containing The Same SHISEIDO COMPANY LTD. (JP) 2011-01-06 US disclosed
EP-2255780-A1 PARAKERATOSIS INHIBITOR, PORE SHRINKING AGENT OR AGENT FOR PREVENTING OR IMPROVING ROUGH SKIN, AND COMPOSITION FOR EXTERNAL USE ON THE SKIN CONTAINING THE SAME Shiseido Company, Ltd. (JP) 2010-12-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110004019-A1 Parakeratosis Inhibitor, Pore-Shrinking Agent, Or Rough Skin Inhibiting/Ameliorating Agent, And External Composition For Skin Containing The Same CUTA, GLRA3, ARGLU1 FOLH1 4099/4885NAALAD2 1692/4885RIMKLA 881/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.